β受体阻滞剂治疗高血压的临床应用建议

2019-07-23 中国老年学和老年医学学会 中华心血管杂志.2019.47(6):443-446.

β受体阻滞剂是心血管疾病常用的治疗药物,用于治疗冠心病、心力衰竭、快速性心律失常、高血压等。近年来,其在高血压治疗中的应用受到质疑,新版欧美及我国高血压指南关于其的使用推荐也有所不同。通过梳理β受体阻滞剂的作用机制、药理特点、临床研究证据及国内外相关指南,经多次专家讨论完成此临床应用建议,旨在促进此类药物的合理使用。

中文标题:

β受体阻滞剂治疗高血压的临床应用建议

发布日期:

2019-07-23

简要介绍:

β受体阻滞剂是心血管疾病常用的治疗药物,用于治疗冠心病、心力衰竭、快速性心律失常、高血压等。近年来,其在高血压治疗中的应用受到质疑,新版欧美及我国高血压指南关于其的使用推荐也有所不同。通过梳理β受体阻滞剂的作用机制、药理特点、临床研究证据及国内外相关指南,经多次专家讨论完成此临床应用建议,旨在促进此类药物的合理使用。

 

拓展指南:高血压相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=β受体阻滞剂治疗高血压的临床应用建议)] GetToolGuiderByIdResponse(projectId=1, id=68b591c001e76a59, title=β受体阻滞剂治疗高血压的临床应用建议, enTitle=, guiderFrom=中华心血管杂志.2019.47(6):443-446., authorId=null, author=, summary=β受体阻滞剂是心血管疾病常用的治疗药物,用于治疗冠心病、心力衰竭、快速性心律失常、高血压等。近年来,其在高血压治疗中的应用受到质疑,新版欧美及我国高血压指南关于其的使用推荐也有所不同。通过梳理β受体阻滞剂的作用机制、药理特点、临床研究证据及国内外相关指南,经多次专家讨论完成此临床应用建议,旨在促进此类药物的合理使用。 , cover=, journalId=null, articlesId=null, associationId=1544, associationName=中国老年学和老年医学学会, associationIntro=, copyright=0, guiderPublishedTime=Tue Jul 23 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>β受体阻滞剂是心血管疾病常用的治疗药物,用于治疗冠心病、心力衰竭、快速性心律失常、高血压等。近年来,其在高血压治疗中的应用受到质疑,新版欧美及我国高血压指南关于其的使用推荐也有所不同。通过梳理β受体阻滞剂的作用机制、药理特点、临床研究证据及国内外相关指南,经多次专家讨论完成此临床应用建议,旨在促进此类药物的合理使用。 </P> <P> </P>拓展指南:<strong>与<font color=red>高血压</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=fd7ec1c001e71843" title="中国高血压防治指南2018年修订版" target=_blank>中国高血压防治指南2018年修订版</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=3699c1c001e583cc" title="2019 THS/TSOC共识:中心血压在高血压临床管理中的应用" target=_blank>2019 THS/TSOC共识:中心血压在高血压临床管理中的应用</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=68d7f1c001e56a96" title="2019 THS/TSOC共识声明:肾脏去神经术治疗高血压" target=_blank>2019 THS/TSOC共识声明:肾脏去神经术治疗高血压</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=56a9d1c001ea8724" title="2019专家建议:接受贝伐单抗治疗的卵巢癌和宫颈癌患者高血压的管理" target=_blank>2019专家建议:接受贝伐单抗治疗的卵巢癌和宫颈癌患者高血压的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d1c6f1c001ea6379" title="高血压患者高容量负荷的评估和管理专家建议" target=_blank>高血压患者高容量负荷的评估和管理专家建议</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E9%AB%98%E8%A1%80%E5%8E%8B" target=_blank>有关高血压更多指南</a></ul>, tagList=[TagDto(tagId=893, tagName=β受体阻滞剂), TagDto(tagId=274, tagName=高血压)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5267, appHits=560, showAppHits=17, pcHits=3149, showPcHits=2261, likes=118, shares=18, comments=4, approvalStatus=1, publishedTime=Wed Aug 07 21:41:12 CST 2019, publishedTimeString=2019-07-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Aug 07 21:41:12 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 23:35:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=β受体阻滞剂治疗高血压的临床应用建议)])
β受体阻滞剂治疗高血压的临床应用建议
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1242007, encodeId=912a124200e40, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/7aeaf4b9c36f43f2a16c9d70777d9ab8/57ab422ee66c4a89a732809040711f06.jpg, createdBy=bdfe5483549, createdName=Svana, createdTime=Tue Aug 30 10:19:38 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974963, encodeId=30ff9e496388, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:47 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371134, encodeId=b8533e113481, content=学习了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Aug 12 02:24:57 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2022-08-30 Svana

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1242007, encodeId=912a124200e40, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/7aeaf4b9c36f43f2a16c9d70777d9ab8/57ab422ee66c4a89a732809040711f06.jpg, createdBy=bdfe5483549, createdName=Svana, createdTime=Tue Aug 30 10:19:38 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974963, encodeId=30ff9e496388, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:47 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371134, encodeId=b8533e113481, content=学习了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Aug 12 02:24:57 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2021-06-19 ms7000001124466419

    关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1242007, encodeId=912a124200e40, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/7aeaf4b9c36f43f2a16c9d70777d9ab8/57ab422ee66c4a89a732809040711f06.jpg, createdBy=bdfe5483549, createdName=Svana, createdTime=Tue Aug 30 10:19:38 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974963, encodeId=30ff9e496388, content=关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88ba5447974, createdName=ms7000001124466419, createdTime=Sat Jun 19 20:01:47 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371134, encodeId=b8533e113481, content=学习了,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Mon Aug 12 02:24:57 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 qingfengqishi5

    学习了,学习了

    0